1. Introduction {#s0005}
===============

Classical hairy cell leukemia is a rare, chronic mature B-cell lymphoproliferative disorder that exhibits specific morphologic, immunohistochemical and immunophenotypic features -- expressing CD20, CD22, CD25, CD11c, CD103, CD123 and annexin A1. In 2011, Tiacci et al. proposed a genetic lesion that accounted for all studied cases of classical hairy cell leukemia---the V600E BRAF mutation, which serves in the RAS signaling cascade to propagate cell survival and division [@bib1]. This mutation has been heralded as a key mutation in the pathogenesis of classical hairy cell leukemia, with BRAF-inhibitors being investigated in clinical trials for relapsed c-HCL [@bib2]. Here we present a rare case of wild type BRAF c-HCL in a newly diagnosed woman of childbearing age.

1.1. Case presentation {#s0010}
----------------------

Fig. 1A. Touch imprint (romanowsky stain) of the bone marrow core shows a oval lymphocyte with slightly dispersed chromatin, and pale blue moderately abundant cytoplasm with a ill-defined ruffled border. B. Bone Marrow core (hematoxylin & eosin stain) is hyper-cellular for age with diffuse sheets of hairy cell infiltrates. C. Immunohistochemical stain CD20 (B-cell marker) highlights the increased diffuse infiltrate of B-cells in the Bone Marrow core. D. Immunohistochemical stain Annexin-1 (lipocortin 1) highlights the hairy cell infiltrate.Fig. 1.

2. Discussion {#s0015}
=============

The differential diagnosis for pancytopenia and splenomegaly in the context of a hypercellular bone marrow and marrow fibrosis, as indicated by the moderate to marked diffuse increase in reticulin fibers (grade 2--3 on a scale of 0--3) includes hairy cell leukemia, myeloid disorders such as myelodysplastic syndromes, myeloproliferative neoplasms, primary myelofibrosis, acute myeloid leukemia and systemic mast cell disease [@bib3]. Based on the morphology of the cells, classical hairy cell leukemia (*c*-HCL), hairy cell leukemia variant (vHCL) and splenic marginal zone lymphoma (SMZL) should be the main diagnostic considerations. The morphology of the atypical lymphocyte in the bone marrow touch imprint ([Fig. 1](#f0005){ref-type="fig"}, A), diffuse infiltrate of the CD20 positive atypical B-cells ([Fig. 1](#f0005){ref-type="fig"}, B&C) in the bone marrow and Annexin-1 ([Fig. 1](#f0005){ref-type="fig"}, D) positivity of these atypical B-cells confirms the diagnosis of classical hairy cell leukemia. The BRAF V600E mutation is considered key to the pathophysiology and diagnosis of c-HCL. In an attempt to confirm Tiacci, Xi et al. found that 11% of the tested population with c-HCL, without IgHV4-34, expressed wild-type BRAF, alluding to an alternate mechanism of action behind the pathophysiology of c-HCL in these patients. However, patients in this study were seeking treatment for relapsed HCL and had completed at least one cycle of cladribine, unlike our patient. While related wild-type BRAF processes like variant Hairy Cell Leukemia (vHCL) and IgHV4-34+ hairy cell leukemia confer poorer prognoses, the prognosis of wild-type BRAF in c-HCL is unknown; nonetheless, with 85--90% rates of CR after one cycle of cladribine, our patient has responded similarly [@bib4], [@bib5]. While BRAF inhibitors, like vemurafenib, have exhibited 30--40% CR and 60% partial response rate in refractory c-HCL, in BRAF wild-type cells, vemurafenib paradoxically increases gene transcription by stimulating the kinase activity of BRAF dimers [@bib6]. Therefore, with case reports documenting BRAF V600 negative c-HCL, we may recommend BRAF screening in exon 15 (v600) and 11 [@bib7]. In addition to this, this case highlights the dilemma surrounding cladribine exposure in a woman of childbearing age attempting to conceive, for which minimal data exists. Cladribine is a purine analog that inhibits the enzyme adenosine deaminase, interfering with the cell\'s ability to transcribe DNA. It is characterized as a FDA pregnancy category D where safety and efficacy in children has not been established. The median age of onset at 52 years and c-HCL shares a 4.2 to 1 male to female predilection, indicating the low prevalence of c-HCL in women of childbearing age [@bib6]. In a PubMed literature search for "cladribine, pregnancy", there is only one case report of successful pregnancy POST cladribine exposure [@bib8]. Further literature search has shown successful splenectomy in a pregnant patient with c-HCL followed by one cycle of cladribine post 6 months breastfeeding, resulting in CR [@bib9].

3. Conclusion {#s0020}
=============

This is a rare case of BRAF V600 mutation negative c-HCL with wild-type IgHV that we know of documented in the literature. Though the long- term prognosis is unknown, initial response to cladribine is similar to V600 BRAF c-HCL.
